Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Gains from Sales and Divestitures (2019 - 2025)

Historic Gains from Sales and Divestitures for Protagonist Therapeutics (PTGX) over the last 7 years, with Q3 2025 value amounting to $75500.0.

  • Protagonist Therapeutics' Gains from Sales and Divestitures changed N/A to $75500.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $75500.0, marking a year-over-year change of. This contributed to the annual value of $316748.0 for FY2024, which is 468.17% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Gains from Sales and Divestitures of $75500.0 as of Q3 2025.
  • Over the past 5 years, Protagonist Therapeutics' Gains from Sales and Divestitures peaked at $316748.0 during Q4 2024, and registered a low of $75500.0 during Q3 2025.
  • Over the past 5 years, Protagonist Therapeutics' median Gains from Sales and Divestitures value was $104712.0 (recorded in 2022), while the average stood at $147548.4.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 4039.89% in 2021, then surged by 17152.67% in 2023.
  • Over the past 5 years, Protagonist Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $78165.0 in 2021, then soared by 38.76% to $108462.0 in 2022, then skyrocketed by 178.98% to $302582.0 in 2023, then grew by 4.68% to $316748.0 in 2024, then crashed by 76.16% to $75500.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $75500.0 for Q3 2025, versus $316748.0 for Q4 2024 and $302582.0 for Q4 2023.